Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 2.6/5
BeiGene

BeiGene (6160 HK)

400
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
16 Mar 2025 23:30

China & HK Strategy: Who Are the Victims of a US Recession?

​Reliance on the US market varies among HK-listed companies, with some having high direct exposure to a recession. Those with low direct exposure...

Logo
354 Views
Share
bearishXiaomi
20 Feb 2025 21:49

Hang Seng Indexes: Announcement Today; Updated Flows (Some Big Ones)

Hang Seng Indexes announces post market close today. There will be changes for the HSI, HSCEI, HSTECH, HSIII and HSCI indices. The net round-trip...

Logo
1.9k Views
Share
bullishTencent
28 Jan 2024 05:56

HK Connect SOUTHBOUND Flows (To 26 Jan 2024); ETFs and High Div SOEs Again BIG Buys, Tech Sold

SOUTHBOUND flows were positive on the week but most of the net buying was in the big two ETFs. The trend of buying low PER high div SOEs continues....

Logo
645 Views
Share
bearishHSBC Holdings
25 Feb 2023 02:17

HSI Index Rebalance: No Changes & Further Delays to Reaching the 80 Member Target

In a surprise, there are no adds/deletes in March. There are some large capping changes that result in a one-way turnover of 2.6% and a one-way...

Logo
706 Views
Share
bullishLi Auto
04 Jan 2023 23:58

HSI Index Rebalance Preview: Better Late Than Never?

Adding 4 stocks gets us to 80 members - a target that was to be reached by mid-2022. We list 10 potential adds where passive trackers will need to...

Logo
1k Views
Share
x